阅读说明：本技术 预防口腔癌的方法 (Method for preventing oral cancer ) 是由 周宇 关晓兵 陈莉 于 2018-05-10 设计创作，主要内容包括：携带miR-185的外泌体预防和治疗口腔癌的方法,以及包含经过改造的唾液外泌体的、用于预防和治疗口腔癌的药物组合物。(A method for preventing and treating oral cancer by using miR-185-carrying exosome, and a pharmaceutical composition for preventing and treating oral cancer, which comprises modified saliva exosome.)

a method of preventing or arresting the conversion of oral leukoplakia to oral cancer comprising administering to a leukoplakia subject a therapeutically effective amount of exosomes carrying miR-185.

The method of claim 1, wherein the white spots are white spot simple hyperplasia, white spot with abnormal hyperplasia.

The method of claim 1 or 2, wherein the oral cancer is oral squamous cell carcinoma.

The method of any one of claims 1 to 3, wherein the miR-185 carrying exosomes are administered with an additional drug or method that prevents the conversion of oral leukoplakia to oral cancer.

A method for treating oral leukoplakia comprising administering to a leukoplakia subject a therapeutically effective amount of exosomes carrying miR-185.

The method of claim 5, wherein the white spots are white spot simple hyperplasia, white spot with abnormal hyperplasia.

The method of claim 5 or 6, wherein the treatment comprises reducing the area of the exudate or eliminating the exudate, or reducing exudate with abnormal proliferation, or reversing to simple proliferation, or converting the exudate to normal.

The method of any one of claims 5 to 7, wherein the miR-185 carrying exosomes are administered with another drug or method of treating oral leukoplakia.

Use of an exosome carrying miR-185 in the preparation of a pharmaceutical composition, kit or pharmaceutical product for preventing or preventing conversion of oral leukoplakia to oral cancer in an oral leukoplakia subject.

The use according to claim 9, wherein the white spots are white spot simple hyperplasia, white spot with abnormal hyperplasia.

The use of claim 9 or 10, wherein the oral cancer is oral squamous cell carcinoma.

The use of any one of claims 9 to 11, wherein the miR-185 carrying exosomes are administered with an additional medicament or method of preventing or arresting the conversion of oral leukoplakia to oral cancer.

The method of any one of claims 1 to 8, the use of any one of claims 9 to 12, wherein said miR-185-bearing exosomes are administered to the subject by a local route of administration.

The method of any one of claims 1 to 8, the use of any one of claims 9 to 12, wherein said miR-185-bearing exosomes are administered to the subject by a submucosal injection, topical application or buccal route.

A method for preventing oral cancer, comprising administering to a subject a prophylactically effective amount of exosomes carrying miR-185, which exosomes prevent conversion of simple leukoplakia into leukoplakia-associated dysplasia and oral cancer or prevent conversion of leukoplakia-associated dysplasia into oral cancer by one or more of: inhibiting inflammatory reaction, inhibiting abnormal proliferation of epithelial cells of oral mucosa, and inhibiting formation of mucosa capillary.

Use of an exosome carrying miR-185 in the preparation of a medicament for preventing oral cancer, wherein the exosome prevents the conversion of simple leukoplakia to leukoplakia with abnormal proliferation and oral cancer or prevents the conversion of leukoplakia with abnormal proliferation to oral cancer by one or more of the following means: inhibiting inflammatory reaction, inhibiting abnormal proliferation of epithelial cells of oral mucosa, and inhibiting formation of mucosa capillary.

An engineered saliva exosome having introduced thereto a prophylactically or therapeutically effective amount of miR-185.

A pharmaceutical composition for preventing or arresting the conversion of oral leukoplakia to oral cancer comprising the engineered saliva exosomes of claim 17.

The composition of claim 18, wherein the white spots are white spot simple hyperplasia, white spot with abnormal hyperplasia.

The composition of claim 18 or 19, wherein the oral cancer is oral squamous cell carcinoma.

A kit or a pharmaceutical product comprising an exosome carrying miR-185 according to claim 17, or a pharmaceutical composition according to any one of claims 18-20.

Application of miR-185 or miR-185-carrying exosomes in preparation of drugs for inhibiting proliferation of oral cancer cells.

Use of miR-185 or miR-185-carrying exosomes in preparation of a medicament for regulating expression of oral cancer cell-associated proteins VEGF and AKT in an oral cancer subject.

The use of claim 23, wherein said modulating comprises inhibiting the expression of oral cancer cell-associated proteins VEGF and AKT.

A method of inhibiting proliferation of oral cancer cells, comprising administering to a subject an effective amount of miR-185 or a miR-185-bearing exosome.

A method of modulating expression of oral cancer cell-associated proteins VEGF and AKT in an oral cancer subject, comprising administering to the subject an effective amount of miR-185 or a miR-185-carrying exosome.

The use of claim 26, wherein said modulating comprises inhibiting the expression of oral cancer cell-associated proteins VEGF and AKT.